The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

BACKGROUND: Natalizumab is efficacious in the treatment of relapsing-remitting multiple sclerosis. All patients receive the same treatment regimen of 300 mg every 4 weeks, despite differences in pharmacokinetics between individual patients. OBJECTIVE: To give neurologists insight into natalizumab co...

Descripción completa

Detalles Bibliográficos
Autores principales: van Kempen, Zoé LE, Leurs, Cyra E, Witte, Birgit I, de Vries, Annick, Wattjes, Mike P, Rispens, Theo, Killestein, Joep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971363/
https://www.ncbi.nlm.nih.gov/pubmed/28485678
http://dx.doi.org/10.1177/1352458517708464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971363/
https://www.ncbi.nlm.nih.gov/pubmed/28485678
http://dx.doi.org/10.1177/1352458517708464

Ejemplares similares